Flatiron Health, Penn Medicine Begin Partnership to Advance Equity of Cancer Care
Collaboration to focus on enabling clinicians to open clinical trials at the point of care.
Flatiron Health announced that it will be partnering with Penn Medicine to bring its Flatiron Assist to Penn’s Abramson Cancer Center (ACC). The project aims to further enable clinicians at ACC to determine and promote site-preferred pathways and open clinical trials at the point of care alongside the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
“At Flatiron, we are committed to elevating clinical care and unlocking the power of patient data, so every person’s experience can inform and improve outcomes for future patients. Partnering with Penn Medicine’s Abramson Cancer Center, a market-leading cancer care provider and a pioneer of digital innovation in healthcare, enables us to use data for good and reimagine the infrastructure of cancer care,” said Julia Morton, SVP, GM, Flatiron HC. “We are looking forward to working together to accelerate the delivery of more standardized, efficient, and effective cancer care across the entire health system.”
Reference: Flatiron Health Launches New Strategic Collaboration to Advance Health Insights and Equity of Cancer Care. BusiessWire. October 23, 2023. Accessed October 23, 2023. https://www.businesswire.com/news/home/20231023565932/en/Flatiron-Health-Launches-New-Strategic-Collaboration-to-Advance-Health-Insights-and-Equity-of-Cancer-Care
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
